CGAS and neoplasm: Shen et al. uncovered that PARPi treatment activated the cGAS/STING pathway and increased tumor infiltrating lymphocytes (TILs), which collectively resulted in an enhanced immunogenic response; the combination treatment of PARPi with immune checkpoint blockade greatly enhanced tumor susceptibility to PD1/PD-L1 administration (Meng et al., 2021).